Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.

Peter Shane Hamblin Arul Earnest Anthony W Russell Stella Samoborec Ella Zomer Sophia Zoungas

Published in: Diabetes, obesity & metabolism (2024)

Utilization of GLDs doubled, and associated costs tripled over the past 11 years, with no sign of either utilization or costs plateauing, predominantly due to increased GLP-1RA and SGLT2 inhibitor prescribing.

Keyphrases

type diabetes
primary care
blood glucose
metabolic syndrome
adipose tissue
glycemic control
ankylosing spondylitis
insulin resistance
adverse drug